 4D pharma plc NASDAQ: LBPS has announced interim results from Phase 12 study evaluating the combination of MRx0518 and Merck Co Incs NYSE: MRK Keytruda pembrolizumab for renal cell carcinoma RCC. The Part B of its signal finding study of MRx0518 . 